Loading
A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) is a phase 3 interventional study registered as NCT06109779 by AstraZeneca, with 760 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2029-01-02. Interventions recorded: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin and S-1 [Tegafur/Oteracil/gimeracil].
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, Gemcitabine + cisplatin, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/